ValuEngine upgraded shares of Moleculin Biotech (NASDAQ:MBRX) from a strong sell rating to a sell rating in a report issued on Friday morning.

Separately, Roth Capital initiated coverage on shares of Moleculin Biotech in a research report on Wednesday, December 20th. They set a buy rating and a $8.00 price target on the stock.

Shares of Moleculin Biotech (NASDAQ:MBRX) opened at $1.79 on Friday. Moleculin Biotech has a 12-month low of $0.71 and a 12-month high of $3.75.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($0.14) EPS for the quarter. research analysts forecast that Moleculin Biotech will post -0.47 earnings per share for the current year.

A hedge fund recently raised its stake in Moleculin Biotech stock. Vanguard Group Inc. increased its position in shares of Moleculin Biotech Inc (NASDAQ:MBRX) by 27.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 337,321 shares of the company’s stock after buying an additional 73,161 shares during the quarter. Vanguard Group Inc. owned about 1.90% of Moleculin Biotech worth $631,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.09% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Moleculin Biotech (MBRX) Raised to “Sell” at ValuEngine” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at

About Moleculin Biotech

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with's FREE daily email newsletter.